

Ref. No: FOI1475
Date: 17/01/2025
Subject: Intra-vitreous injections

REQUEST

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2024:

- Bevacizumab
- Fluocinolone acetonide

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2024:

Eye conditions: Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) and Retinal Vein Occlusion (RVO)

RESPONSE

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2024:

- Aflibercept – Eylea - 1038
- Brolucizumab Beovu - <5
- Dexamethasone - Ozurdex - 50
- Faricimab – vabysmo -554
- Ranibizumab – Lucentis- <5
- Ranibizumab - Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)- 507

2. Please provide the number of injections/implants by eye condition for the four-month period from September to December 2024:

Eye conditions: Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Oedema (DMO) and Retinal Vein Occlusion (RVO)

Injections from September- December:

Wet Age-Related Macular Degeneration (wAMD) – injections 196

Diabetic Macular Oedema (DMO) -221

Retinal Vein Occlusion (RVO)- 188

BRVO- 54

CRVO-29

HRVO-<5

INRVO-<5

SBRVO- <5

Due to the low number of patients on these drugs which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.